Despite a recent price target cut from Morgan Stanley, analysts maintain that Oracle's strategic investments in GPU-as-a-Service and its deepening ties with TikTok position it for long-term cloud growth, even as capital expenditures weigh on short-term earnings.
The Producer Price Index jumped 0.5% last month, more than double November's increase, as rising costs for machinery, metals, and travel services pointed to persistent pipeline pressures for consumers.
While an IRS extension grants an extra six months to file, experts caution that the April 15 payment deadline is non-negotiable. We break down the process, benefits, and common pitfalls for the millions considering this option.
While the financial sector remains the economy's cornerstone, policy headwinds have capped its recent performance. We analyze one credit rater and a fintech disruptor that show resilience, alongside a legacy asset manager facing challenges.
While small-cap stocks can offer high-growth potential, their path is often fraught with operational challenges and valuation risks. We examine three companies where the risks may outweigh the rewards in the current market environment.
While the small-cap index is famed for its hidden gems, some constituents face headwinds that make them less compelling for growth-focused portfolios. Here's a look at three companies analysts are currently avoiding.
Comcast (CMCSA) edged past profit forecasts in its latest quarter, driven by strong wireless subscriber growth and early signs that its push for simpler broadband pricing is resonating with customers. The media giant now sets its sights on converting promotional users and doubling down on network investments.
Amidst a market rally driven by a handful of tech giants, certain volatile stocks present outsized risks. We examine three names where valuation concerns and sector headwinds warrant a cautious approach.
The business services sector has outperformed, riding a wave of corporate demand for efficiency. But with economic sensitivity looming, we analyze two companies with robust models and one where caution may be warranted.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze one company whose competitive moat continues to widen and two others where valuation and market dynamics suggest caution is warranted.
Despite CEO Satya Nadella touting strong adoption of Copilot AI assistants, Microsoft's stock dipped as investors express unease over massive capital expenditures and growth concerns in core Azure and 365 businesses.
CNBC's Jim Cramer suggests Intel shares could surge significantly, as the chipmaker's strategic overhaul and analyst upgrades fuel investor optimism amid a 140% yearly gain.
Michigan's Attorney General has formally demanded the return of state funds from Gotion Inc., a Chinese battery manufacturer, following the collapse of its planned $2.4 billion facility. The move highlights growing tensions over foreign investment in U.S. strategic industries.
Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
Campbell Soup Company will shutter its Hyannis, Massachusetts facility, the original home of Cape Cod Potato Chips, citing economic inefficiency. The closure, affecting 49 jobs, marks a strategic shift of production to larger plants as the snack giant consolidates its network.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
While the allure of finding the next undervalued gem is strong, some stocks trading at low multiples may be cheap for a reason. We examine three companies where fundamental challenges could outweigh their seemingly attractive valuations.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
